Americans want Congress and the president to step in if CMS doesn’t change its restrictive coverage policy. WASHINGTON (May 23, 2023) — Nearly nine in ten voters favor (87% favor, 77% strongly favor) requiring Medicare to cover the cost of FDA-approved drugs that can slow the progression of Alzheimer’s disease, according to a new poll […]
“GAP strongly encourages ICER to revamp its model to accurately reflect Leqembi’s benefits and what matters most to patients and their families” For immediate release: Washington, D.C. (March 17, 2023) — Joining other Alzheimer’s advocates, experts and researchers, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer provided written comments as part of the Institute for […]
“Today, the Veterans Health Administration (VA) demonstrated enormous leadership and concern for the health of veteran’s fighting Alzheimer’s disease with its decision to cover the cost of Leqembi. Our veterans battled for us, and the VA is now giving their patients new therapies to battle Alzheimer’s.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: […]
Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 27, 2023) — “On behalf of the of the thousands of trial participants, clinicians and researchers who are part of the Global Alzheimer’s Platform Foundation (GAP) network, we want to thank and honor Dr. Billy Dunn for his leadership and scientific contributions, which […]
“CMS’s latest decision on disease-modifying therapies for Alzheimer’s patients is effectively a coverage denial for this entire class of drugs, and patients will needlessly die as a result of it.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 23, 2023) — “Once again, the Centers for Medicare and Medicaid Services (CMS) […]
The Global Alzheimer’s Platform Foundation’s® (GAP) 2022 Citizen Scientist Award recipients include the first husband-and-wife volunteer team, an Alzheimer’s advocate who champions participation in prevention studies, and a Parkinson’s disease clinical trial participant who volunteers in research studies to find hope after diagnosis WASHINGTON, DC (Feb. 22, 2023) — Today, the Global Alzheimer’s Platform Foundation […]
The Global Alzheimer’s Platform Foundation® adds Lammert Albers to its team in the role of chief commercial officer; he joins GAP with leadership experience in growing clinical trial and life science technology companies WASHINGTON, DC (Feb. 21, 2023) — The Global Alzheimer’s Platform Foundation (GAP) welcomes Lammert Albers to its leadership team. Lammert has successfully […]
The Global Alzheimer’s Platform Foundation® (GAP) kicks off its annual conference in Austin, Texas, bringing together the nation’s leading Alzheimer’s researchers, scientists and advocates” WASHINGTON, DC (Feb. 20, 2023) — The Global Alzheimer’s Platform Foundation (GAP) will kick off its annual research conference Feb. 22–24 in Austin, Texas. The conference brings together leading Alzheimer’s scientists, […]
“With this approval, it is incumbent on Center for Medicare and Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and the drug’s sponsors to offer this life-changing therapy to patients quickly, while prioritizing access and economic fairness.” Statement attributed to Global Alzheimer’s Platform Foundation President John Dwyer: Washington, D.C. (Jan. 6, 2023) — We applaud the Food […]
Washington, DC — December 23, 2022–Appropriations bills are not simply about funding. They are about people. That is why we are grateful that Congress prioritized funding for accelerated and disruptive Alzheimer’s disease research in the 2023 Omnibus Appropriations Bill. Increases in funding for the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes […]